Our Privacy Statement & Cookie Policy

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.

I agree

People with two copies of a risk gene have genetic form of Alzheimer's

CGTN

A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Center at the Department of Readaptation and Geriatrics of the University Hospital, Geneva, Switzerland, June 6, 2023. /Reuters
A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Center at the Department of Readaptation and Geriatrics of the University Hospital, Geneva, Switzerland, June 6, 2023. /Reuters

A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Center at the Department of Readaptation and Geriatrics of the University Hospital, Geneva, Switzerland, June 6, 2023. /Reuters

People who carry two copies of the APOE4 gene are virtually guaranteed to develop Alzheimer's and face symptoms at an earlier age, researchers reported on Monday in a study that could redefine such carriers as having a new genetic form of the mind-wasting disease.

The reclassification could change Alzheimer's research, diagnosis and approaches to treatment, according to the researchers, whose study was published in the journal Nature Medicine.

"Through these data we are saying that perhaps this is a genetic form of this disease, not merely a risk factor indication," study co-author Sterling Johnson of the University of Wisconsin's Alzheimer's Disease Research Center said in a briefing.

Scientists have known for three decades that people with two copies of the APOE4 gene variant have a significantly higher risk of developing the disease than people with the most common version of the APOE gene, known as APOE3. About 2 to 3 percent of the general population, or 15 percent of people with Alzheimer's, have two copies of the APOE4 variant.

"This study adds compelling data to suggest that people with two copies of this gene are almost guaranteed to develop Alzheimer's if they live long enough, and that they will develop Alzheimer's earlier than people without this gene," said professor Tara Spires-Jones, an Alzheimer's researcher at the University of Edinburgh who was not involved in the study.

Juan Fortea of the University of Barcelona and colleagues studied more than 3,000 donated brains from the U.S. National Alzheimer's Coordinating Center, as well as biological and clinical data on more than 10,000 individuals from three countries.

They found that by age 65, at least 95 percent of people with two copies of APOE4 – known as homozygotes – had abnormal levels of an Alzheimer's-related protein called beta amyloid in their spinal fluid, and 75 percent had positive brain scans for amyloid.

Nearly all APOE4 homozygotes in the study had higher levels of amyloid at age 65 than people who did not carry the risk variant.

The findings suggest APOE4 homozygotes meet the three main criteria for being a genetic disease: nearly everyone with these two variants has Alzheimer's biology; they develop symptoms at about the same rate; and clinical and biological changes occur in a predictable sequence, the researchers said.

Professor David Curtis of the UCL Genetics Institute, who was not involved in the research, remained unconvinced. "I do not see anything in this paper to justify the claim that carrying two copies of APOE4 represents some 'distinct genetic form' of Alzheimer's disease'," he said in a statement.

"No matter how many (copies) of APOE4 one carries the underlying disease processes seem similar across cases of Alzheimer's disease," he said.

Source(s): Reuters
Search Trends